Overview
Generalized eruptive histiocytosis (GEH) is a rare non-Langerhans cell histiocytosis characterized by the widespread eruption of small, firm, red-brown to skin-colored papules distributed symmetrically over the face, trunk, and proximal extremities. The condition results from a benign proliferation of histiocytes (tissue macrophages) in the skin. GEH primarily affects the integumentary system (skin), though mucosal involvement has occasionally been reported. The papules are typically asymptomatic or mildly pruritic, measuring 2–10 mm in diameter, and tend to appear in successive crops. Histologically, the lesions show a dermal infiltrate of mononuclear histiocytes without lipidization, Touton giant cells, or significant inflammatory infiltrate. Immunohistochemistry is positive for CD68 and negative for CD1a and S-100, distinguishing it from Langerhans cell histiocytosis. GEH is generally considered a benign and self-limiting condition, with lesions often resolving spontaneously over months to years, sometimes leaving hyperpigmented macules or slight atrophy. However, some cases have been reported to progress to or be associated with other forms of non-Langerhans cell histiocytosis, such as xanthoma disseminatum or progressive nodular histiocytosis, suggesting that GEH may represent an early or transitional phase within a spectrum of histiocytic disorders. Rarely, GEH has been reported in association with hematologic malignancies. There is no established standard treatment for generalized eruptive histiocytosis given its typically self-resolving nature. Management is generally expectant with clinical monitoring. In cases where lesions are persistent, cosmetically bothersome, or symptomatic, treatments that have been tried with variable success include topical or systemic corticosteroids, isotretinoin, PUVA phototherapy, and dapsone. Patients require follow-up to monitor for potential progression to other histiocytic disorders or development of associated systemic conditions.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Generalized eruptive histiocytosis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Generalized eruptive histiocytosis at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Generalized eruptive histiocytosis.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Generalized eruptive histiocytosis.
Community
No community posts yet. Be the first to share your experience with Generalized eruptive histiocytosis.
Start the conversation →Latest news about Generalized eruptive histiocytosis
No recent news articles for Generalized eruptive histiocytosis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Generalized eruptive histiocytosis
What is Generalized eruptive histiocytosis?
Generalized eruptive histiocytosis (GEH) is a rare non-Langerhans cell histiocytosis characterized by the widespread eruption of small, firm, red-brown to skin-colored papules distributed symmetrically over the face, trunk, and proximal extremities. The condition results from a benign proliferation of histiocytes (tissue macrophages) in the skin. GEH primarily affects the integumentary system (skin), though mucosal involvement has occasionally been reported. The papules are typically asymptomatic or mildly pruritic, measuring 2–10 mm in diameter, and tend to appear in successive crops. Histolo
How is Generalized eruptive histiocytosis inherited?
Generalized eruptive histiocytosis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Generalized eruptive histiocytosis typically begin?
Typical onset of Generalized eruptive histiocytosis is adult. Age of onset can vary across affected individuals.